Primera Conferencia Ministerial Mundial de la OMS
Poner fin a la tuberculosis en la era del desarrollo sostenible: Una respuesta multisectorial
Moscú (Federación de Rusia), 16-17 de noviembre de 2017
Tackling Tuberculosis in Under-Served Populations: A Resource for TB Control Boards and their partners
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
Un análisis desde la perspectiva del sector de la salud en América Latina y el Caribe
Washington, D.C., 2017
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
5th revised edition.
This document provides a ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. The current revision took place at the seventh meeting of the AGISAR held in Raleigh, United States of America in 2016.
Application of a One Health approach .
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillan...ce of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach.
more
These guidelines present evidence-based recommendations and best practice statements on use of medically important antimicrobials in food-producing animals, based on the WHO list of critically important antimicrobials for human medicine (WHO CIA List). These guidelines aim primarily to help preserve... the effectiveness of medically important antimicrobials, particularly those antimicrobials judged to be critically important to human medicine and also help preserve the effectiveness of antimicrobials for veterinary medicine, in direct support of the WHO global action plan on antimicrobial resistance
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Uptsate 2017
Global HIV Strategic Information Working Group
For Populations At Risk For HIV